PNC-27
PNC-27 is a groundbreaking anti-cancer peptide that selectively kills cancer cells by binding to HDM-2 protein on cancer cell membranes, then forming transmembrane pores that trigger immediate necrotic cell death through osmotic lysis—without requiring p53 tumor suppressor genes, allowing it to work against p53-null cancers resistant to conventional therapy. Laboratory studies show nearly 100% cancer cell elimination in leukemia and breast cancer lines while leaving normal cells completely unharmed due to HDM-2 expression exclusively on cancer cell membranes.
Route
Subcutaneous injection
Dose range
100 mcg – 500 mcg
Frequency
Once per day (subcutaneous)
Cycle length
8–12 weeks
Overview
PNC-27 is a groundbreaking anti-cancer peptide that selectively kills cancer cells by binding to HDM-2 protein on cancer cell membranes, then forming transmembrane pores that trigger immediate necrotic cell death through osmotic lysis—without requiring p53 tumor suppressor genes, allowing it to work against p53-null cancers resistant to conventional therapy. Laboratory studies show nearly 100% cancer cell elimination in leukemia and breast cancer lines while leaving normal cells completely unharmed due to HDM-2 expression exclusively on cancer cell membranes.
The p53-independent mechanism overcomes a major cancer vulnerability: many advanced cancers lose p53 function, rendering standard therapies ineffective. PNC-27 works independently of p53 status, potentially making it effective where all conventional drugs fail. Its selectivity for cancer cells (avoiding normal cell damage) addresses the toxicity limitations plaguing chemotherapy. Research shows whole-peptide integrity is critical—fragmentation eliminates activity—making it a sophisticated targeted approach rather than blunt chemotoxicity. For advanced, treatment-resistant, or p53-deficient cancers where conventional options are exhausted, PNC-27 represents a novel mechanism offering genuine hope through selective cancer cell destruction.
Studied benefits
- An anti-cancer peptide that targets the HDM-2 protein
- It is designed to selectively bind to the membranes of cancer cells, causing them to undergo rapid pore formation and cell death (lysis) while leaving healthy, non-cancerous cells untouched
Reported side effects
- Clinical data in humans is still emerging
- Some research observations note potential localized pain or inflammatory responses at the site of administration as the body processes the targeted cell breakdown
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
PNC-27 (30 mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 10 mg/mL).
Educational exploration of a p53-derived peptide studied preclinically for selective cancer-cell membrane disruption.
| Week | Daily Dose (mcg) | Draw at 10 mg/mL | Log |
|---|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 units (0.01 mL) | + Log |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) | + Log |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) | + Log |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) | + Log |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Any consistent time; rotate injection sites.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
10 mg/mL
300 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 8-week cycle) you would use about 5.6 mg, i.e. 1 × 30 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a nutrient-dense, anti-inflammatory diet rich in cruciferous vegetables and antioxidants to support the body’s innate cellular defense mechanisms during research. Stay physically active with moderate exercise to help the body process and eliminate cellular debris, which is critical when studying peptides that target the HDM2-p53 interaction. Ensure 7–9 hours of quality sleep to support the tissue remodeling and immune system vigilance that follow cellular apoptosis. Adhere to strict research protocols and consult with qualified professionals, as this peptide is primarily studied for its ability to induce selective necrosis in malignant cells while sparing healthy tissue.
Evidence
Research summaries
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Findings: Induces selective membranolysis in cancer cells (100% killing in 90 min at high doses), spares untransformed cells, eradicates tumors in nude mice, HDM-2 membrane expression as tumor biomarker
In this foundational PNAS study, researchers confirmed PNC-27's 3D structure superimposes on p53(17-26)-HDM-2 crystal (rms deviation 1.7-2.5 Å), enabling native binding. Western blots showed HDM-2 enriched 4-9 fold in membranes of cancer lines (MIA-PaCa-2 pancreatic, MCF-7 breast, A-2058 melanoma) vs. untransformed controls (MCF-10-2A, AG13145 fibroblasts). Confocal microscopy revealed colocalization (yellow fluorescence) of fluorescent PNC-27 with HDM-2 in cancer membranes within minutes, absent in normal cells. Co-IP confirmed specific binding (blocked by excess unlabeled PNC-27/28, not PNC-29 control). Transfecting membrane-targeted HDM-2 (HDM-2-CVVK) into MCF-10-2A rendered them susceptible: LDH release doubled, viability dropped 3-fold vs. controls (p<0.01), without apoptosis (no caspase rise). PNC-27 remained intact (double-fluorophore intact) during lysis. In vivo, prior work showed tumor regression in mice. Mechanistic insight: HDM-2 anchors PNC-27 in cancer membranes for pore formation; normal cells lack this, allowing peptide degradation/entry without lysis. This selectivity exploits cancer-specific HDM-2 translocation, offering a novel membranolytic paradigm vs. traditional apoptosis inducers.
Read the study ↗Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Findings: Kills AML lines (U937, OCI-AML3, HL-60) via 100% necrosis/LDH release in 4 hours, spares murine leukocytes/lymphocytes, potential for hematologic malignancies
Flow cytometry confirmed high HDM-2 membrane expression on three AML lines: U937 (monocytic), OCI-AML3 (myelomonocytic), HL-60 (promyelocytic). PNC-27 (dose-dependent, 50-200 μg/ml) bound membrane HDM-2, triggering necrosis (MTT viability <10%, LDH release >80% in 4h) without annexin V/caspase-3 apoptosis. Normal hematopoietic controls showed no HDM-2 membrane signal, no cytotoxicity (LDH <10%). Colocalization microscopy showed PNC-27-HDM-2 overlap in leukemia membranes. Mechanism: pore formation extrudes contents selectively. Why significant? AML often resists apoptosis-based therapies; PNC-27's necrosis bypasses this, targeting primitive/stem-like cells (HL-60/K562 models). Ex vivo expansion suggests bedside translation potential for refractory leukemia, where HDM-2 membranosis correlates with poor prognosis.
Read the study ↗The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells
Findings: 100% necrosis in p53-null K562 leukemia (stem-like) via LDH release, HDM-2 membranosis in early/non-solid tumors, p53-independent
K562 (p53-homozygously deleted, stem/primitive leukemia) expressed abundant membrane HDM-2 (confirmed microscopy/Western). PNC-27 colocalized with HDM-2, inducing near-100% killing (LDH release) vs. no effect on murine leukocytes. Caspase-3/7 negative (necrosis confirmed). Controls (PNC-29) inert. Extends prior solid tumor work to non-solid/hematologic, proving mechanism holds for stem-like cells lacking p53. Tumor specificity: normal cells degrade PNC-27; cancer HDM-2 stabilizes it for ly
Read the study ↗Identification
Chemistry
- cas
- 1159861-00-3 (primary)
- formula
- C₁₈₈H₂₉₃N₅₃O₄₄S
- molecular weight
- 4031.7-4031.73 g/mol (Da)
- sequence
- H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH (32 amino acids)
- source
- Synthetic; engineered chimeric peptide combining p53 HDM-2-binding domain with cell-penetrating sequence
- biosynthesis
- Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS)
- type
- Linear peptide with alpha-helix-loop-alpha-helix three-dimensional architecture when in aqueous solution; adopts "U-shaped helix-coil-helix" structure in membrane-mimetic environments
Keep exploring